Agios Pharmaceuticals (AGIO) Total Liabilities (2012 - 2026)

Agios Pharmaceuticals (AGIO) has 15 years of Total Liabilities data on file, last reported at $82.4 million in Q2 2026.

• Quarterly Total Liabilities fell 18.96% year-over-year to $82.4 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $82.4 million (down 18.96% YoY) and the FY2025 annual result came in at $104.1 million, down 14.83% from the prior year.
• Total Liabilities grew to $82.4 million in Q2 2026, from $75.9 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $165.1 million in Q3 2024 to a low of $75.9 million in Q1 2026.
• A 5-year average of $114.8 million and a median of $117.6 million in 2023 frame the typical range for Total Liabilities.
• Annual changes were most pronounced in 2024 — Total Liabilities surged 37.13% — and 2025, when it plunged 38.61%.
• Tracing AGIO's Total Liabilities over 5 years: stood at $137.9 million in 2022, then decreased by 8.56% to $126.1 million in 2023, then decreased by 3.06% to $122.2 million in 2024, then dropped by 14.83% to $104.1 million in 2025, then dropped by 20.85% to $82.4 million in 2026.
• The last three Total Liabilities figures came in at $82.4 million (Q2 2026), $75.9 million (Q1 2026), and $104.1 million (Q4 2025), per Business Quant data.